Patents by Inventor David Edward Clark

David Edward Clark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11878150
    Abstract: The present disclosure relates to medicament injection devices. An injection device includes: a movable dosage programming component comprising a rotary encoder system having a predefined angular periodicity, a sensor arrangement including a first optical sensor configured to detect movement of the movable dosage programming component relative to the sensor arrangement during dosing of a medicament, wherein the first optical sensor is configured to operate in a strobe-sampling mode at a first frequency, a second optical sensor configured to detect movement of the rotary encoder system relative to the second optical sensor wherein the second optical sensor is configured to operate in a strobe-sampling mode at a second frequency lower than the first frequency, and a processor arrangement configured to, based on the detected movement, determine a medicament dosage administered by the injection device.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: January 23, 2024
    Assignee: Sanofi
    Inventors: Michael Schabbach, Anthony Paul Morris, Ronald Antony Smith, Brian Charles Molyneux, Paul Richard Draper, Craig Ashley Mason, Oliver Charles Gazeley, Daniel Edward Clark, David Aubrey Plumptre, Aidan Michael O'Hare, Richard James Thomas, Felix Kramer, Beat Wyss, Philipp Muller
  • Publication number: 20240016941
    Abstract: The invention provides a combinations and pharmaceutical compositions comprising (i) a compound which is an indane according to Formula (I) or a pharmaceutically acceptable salt thereof; and (ii) one or more CFTR modulator; wherein R1, R2, R3, R4, n, Lk, (A), G and m are as defined herein. Also provided are therapeutic uses of such combinations and compositions in the treatment of conditions such as cystic fibrosis.
    Type: Application
    Filed: March 23, 2021
    Publication date: January 18, 2024
    Applicant: Antabio SAS
    Inventors: Martin Everett, Simon Leiris, David Thomas Davies, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
  • Patent number: 11813439
    Abstract: The present disclosure relates to medicament injection devices. An injection device includes: a movable dosage programming component comprising a rotary encoder system having a predefined angular periodicity, a sensor arrangement including a first optical sensor configured to detect movement of the movable dosage programming component relative to the sensor arrangement during dosing of a medicament, wherein the first optical sensor is configured to operate in a strobe-sampling mode at a first frequency, a second optical sensor configured to detect movement of the rotary encoder system relative to the second optical sensor wherein the second optical sensor is configured to operate in a strobe-sampling mode at a second frequency lower than the first frequency, and a processor arrangement configured to, based on the detected movement, determine a medicament dosage administered by the injection device.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: November 14, 2023
    Assignee: Sanofi
    Inventors: Michael Schabbach, Anthony Paul Morris, Ronald Antony Smith, Brian Charles Molyneux, Paul Richard Draper, Craig Ashley Mason, Oliver Charles Gazeley, Daniel Edward Clark, David Aubrey Plumptre, Aidan Michael O'Hare, Richard James Thomas, Felix Kramer, Beat Wyss, Philipp Müller
  • Publication number: 20230139502
    Abstract: The invention provides aza-heterocyclyl carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxC activity.
    Type: Application
    Filed: April 27, 2022
    Publication date: May 4, 2023
    Inventors: Michael Dominic Ryan, Thomas David Pallin, Toby Jonathan Blench, Toby Matthew Grover Mullins, David Edward Clark, Emanuela Gancia, Nadia Mamoona Ahmad
  • Patent number: 11613527
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: March 28, 2023
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson, Alessandro Mazzacani, Michael John Stocks, Thomas Matthew Baker, Matthew Robert Conroy, Alun John Smith, David Edward Clark
  • Publication number: 20220363668
    Abstract: The present invention provides compounds of formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined herein.
    Type: Application
    Filed: February 13, 2020
    Publication date: November 17, 2022
    Inventors: Hannah Joy EDWARDS, David Michael EVANS, Alessandro MAZZACANI, Alicja Stela OBARA, David Edward CLARK, Emanuela GANCIA, Rachael PITTAWAY, Joseph William WRIGGLESWORTH
  • Publication number: 20220289727
    Abstract: The present invention provides compounds of formula (I) or (Ia) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, n, R2, R3, R4, R5, and R6 are as defined herein.
    Type: Application
    Filed: February 13, 2020
    Publication date: September 15, 2022
    Inventors: Mitchell Lewis CHILDS, Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Alessandro MAZZACANI, David Edward CLARK, Paul Stuart HINCHLIFFE, Thomas Matthew BAKER, Colin Peter SAMBROOK SMITH, Alun John SMITH, Joseph William WRIGGLESWORTH, Xuezheng YANG
  • Publication number: 20220112169
    Abstract: The invention relates to a compound which is an indane according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, L, n and p are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics.
    Type: Application
    Filed: July 25, 2019
    Publication date: April 14, 2022
    Applicant: Antabio SAS
    Inventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
  • Publication number: 20220048894
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Application
    Filed: October 8, 2021
    Publication date: February 17, 2022
    Inventors: Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Alessandro MAZZACANI, Michael John STOCKS, Thomas Matthew BAKER, Matthew Robert CONROY, Alun John SMITH, David Edward CLARK
  • Publication number: 20210347748
    Abstract: The invention relates to a compound which is an indane according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, n and p are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics.
    Type: Application
    Filed: July 25, 2019
    Publication date: November 11, 2021
    Applicant: Antabio SAS
    Inventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
  • Publication number: 20210284639
    Abstract: The invention relates to compounds of formula I inhibiting Rho Kinase that are bicyclic dihydropyrimidine-carboxamide derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: July 12, 2019
    Publication date: September 16, 2021
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Alessandro ACCETTA, Fabio RANCATI, Anna Maria CAPELLI, David Edward CLARK, Patrizia TISSELLI, Christine EDWARDS, Amaud Jean Francois Auguste CHEGUILLAUME, Gurdip BHALAY
  • Publication number: 20210253568
    Abstract: The invention relates to compounds of formula I inhibiting Rho Kinase that are azaindole derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: June 11, 2019
    Publication date: August 19, 2021
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Alessandro ACCETTA, Fabio RANCATI, David Edward CLARK, Christine EDWARDS
  • Patent number: 11000511
    Abstract: The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p, q, L, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: May 11, 2021
    Assignee: Antabio SAS
    Inventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Jonathan Mark Sutton, Michael Steven Bodnarchuk, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, David Edward Clark, Richard Leonard Elliott, Lilha Beyria
  • Patent number: 10954236
    Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: March 23, 2021
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay, Arnaud Jean Francois Auguste Cheguillaume
  • Publication number: 20200360614
    Abstract: The present disclosure relates to medicament injection devices. An injection device includes: a movable dosage programming component comprising a rotary encoder system having a predefined angular periodicity, a sensor arrangement including a first optical sensor configured to detect movement of the movable dosage programming component relative to the sensor arrangement during dosing of a medicament, wherein the first optical sensor is configured to operate in a strobe-sampling mode at a first frequency, a second optical sensor configured to detect movement of the rotary encoder system relative to the second optical sensor wherein the second optical sensor is configured to operate in a strobe-sampling mode at a second frequency lower than the first frequency, and a processor arrangement configured to, based on the detected movement, determine a medicament dosage administered by the injection device.
    Type: Application
    Filed: November 23, 2018
    Publication date: November 19, 2020
    Inventors: Michael Schabbach, Anthony Paul Morris, Ronald Antony Smith, Brian Charles Molyneux, Paul Richard Draper, Craig Ashley Mason, Oliver Charles Gazeley, David Edward Clark, David Aubrey Plumptre, Aidan Michael O`Hare, Richard James Thomas, Felix Kramer, Beat Wyss, Philipp Müller
  • Publication number: 20200155509
    Abstract: The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p, q, L, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.
    Type: Application
    Filed: March 21, 2018
    Publication date: May 21, 2020
    Applicant: Antabio SAS
    Inventors: Simon LEIRIS, David Thomas DAVIES, Martin EVERETT, Nicolas SPRYNSKI, Jonathan Mark SUTTON, Michael Steven BODNARCHUK, Thomas David PALLIN, Andrew Peter CRIDLAND, Toby Jonathan BLENCH, David Edward CLARK, Richard Leonard ELLIOTT, Lilha BEYRIA
  • Publication number: 20200079774
    Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: October 18, 2019
    Publication date: March 12, 2020
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Alessandro ACCETTA, Fabio RANCATI, Anna Maria CAPELLI, David Edward CLARK, Patrizia TISSELLI, Christine EDWARDS, Gurdip BHALAY, Arnaud Jean Francois Auquste CHEGUILLAUME
  • Patent number: 10584128
    Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: March 10, 2020
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay
  • Patent number: 10501461
    Abstract: Tyrosine amide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: December 10, 2019
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay, Arnaud Jean Francois Auguste Cheguillaume
  • Patent number: 10493071
    Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: December 3, 2019
    Assignee: HELPERBY THERAPEUTICS LIMITED
    Inventors: Petra Helga Beck, Marc Barry Brown, David Edward Clark, Anthony Coates, Hazel Joan Dyke, Yanmin Hu, Derek John Londesbrough, Keith Mills, Thomas David Pallin, Gary Patrick Reid, Gerlinda Stoddart